- GlobeNewswire•25 days ago
THE WOODLANDS, Texas, Feb. 02, 2017-- Repros Therapeutics Inc. ® today announced that Joseph S. Podolski is leaving his position as President and Chief Executive Officer and member of the Board of Directors ...
- GlobeNewswire•28 days agoFDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids
THE WOODLANDS, Texas, Jan. 30, 2017-- Repros Therapeutics Inc. ® today announced the FDA has granted an“ end of Phase 2” meeting to discuss the Phase 3 requirements to demonstrate both efficacy and safety ...
- GlobeNewswire•2 months agoRepros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis
THE WOODLANDS, Texas, Dec. 19, 2016-- Repros Therapeutics Inc. ® today announced it has requested a meeting to discuss Phase 3 requirements for the development of Proellex ® for the treatment of endometriosis. ...
RPRX : Summary for Repros Therapeutics Inc. - Yahoo Finance
Repros Therapeutics Inc. (RPRX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.95 x 200|
|Ask||1.88 x 200|
|Day's Range||1.12 - 1.20|
|52 Week Range||0.81 - 3.48|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.47|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|